The race for a Covid vaccine: inside the Australian lab working round the clock to produce 100m
mRNA Covid-19 vaccines: Facts vs Fiction
COVID-19 vaccines: McGill researchers track the global race
COVID-19 vaccine development: What′s the progress?
Covid-19 Vaccine Research
VIDEO
COVID-19 Vaccine Clinical Trial Volunteers Share What Being Part of the Trial Meant to Them
You And Vaccine
How Many Times Did He Get the Dose of COVID-19 Vaccine?😲
COMMENTS
COVID-19 Vaccines
By the end of November 2021, scientists estimate that mRNA COVID-19 vaccines had prevented at least 1 million deaths, 10 million hospitalizations, and 36 million SARS-CoV-2 infections in the United States. Sometimes people who are fully vaccinated get a breakthrough infection, meaning that they test positive for SARS-CoV-2 or become ill with ...
Covid-19 Vaccines
The protective effects of vaccination and prior infection against severe Covid-19 are reviewed, with proposed directions for future research, including mucosal immunity and intermittent vaccine boo...
Safety & effectiveness of COVID-19 vaccines: A narrative review
Safety and adverse effects of current COVID-19 vaccines. As shown in Table I, current vaccines have demonstrated considerable efficacy in diminishing mild, moderate and severe cases with a low risk of adverse events 21.For some of these vaccines [such as Convidicea (AD5-nCoV), Janssen (Ad26.COV2.S), Sinopharm (BBIBP-CorV), Covaxin (BBV152) and Sinovac (CoronaVac)], there is the information ...
Long-term effectiveness of COVID-19 vaccines against infections
Our analyses indicate that vaccine effectiveness generally decreases over time against SARS-CoV-2 infections, hospitalisations, and mortality. The baseline vaccine effectiveness levels for the omicron variant were notably lower than for other variants. Therefore, other preventive measures (eg, face-mask wearing and physical distancing) might be necessary to manage the pandemic in the long term.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Discussion. A two-dose regimen of BNT162b2 (30 μg per dose, given 21 days apart) was found to be safe and 95% effective against Covid-19. The vaccine met both primary efficacy end points, with ...
COVID-19 vaccines: Current evidence and considerations
Abstract. The coronavirus disease 2019 (COVID-19) pandemic is a global crisis, with devastating health, business and social impacts. Vaccination is a safe, simple, and effective way of protecting a person against COVID-19. By the end of August 2021, only 24.6% of the world population has received two doses of a COVID-19 vaccine.
Coronavirus disease (COVID-19): Vaccine research and development
Now, given the urgent need for COVID-19 vaccines, unprecedented financial investments and scientific collaborations are changing how vaccines are developed. This means that some of the steps in the research and development process have been happening in parallel, while still maintaining strict clinical and safety standards.
Efficacy of COVID-19 vaccines: From clinical trials to real life
COVID-19 vaccine development: an unprecedented timeframe. In the last decade, there was a marked evolution of vaccine platforms including the development of nucleic acid-based vaccine candidates and vectored vaccines, a number of approaches that have been used to accelerate COVID-19 vaccines elaboration.
Experimental coronavirus vaccine highly effective
Clinical trial results showed that the investigational vaccine known as mRNA-1273 is 94.1% effective in preventing symptomatic COVID-19. The findings suggest that the vaccine, which has now been FDA-approved for emergency use, is safe and effective. Results from a clinical trial showed that a COVID-19 vaccine developed by NIH and the biotech ...
Evaluating COVID-19 vaccines in the real world
The effectiveness of the mRNA vaccines in preventing COVID-19 disease progression in 2021 set new expectations about the role of prevention interventions for the disease. Efficacy observed in the trials was more than 90%.1,2 The efficacy of other vaccines evaluated in large randomised trials, such as the Oxford-AstraZeneca (70%) and Sputnik V (91%) vaccines, have been criticised for elements ...
Home
Find COVID-19 datasets, data tools, and publications to use in research. EXPLORE COVID-19 DATA. Learn how NIH is supporting research in COVID-19 testing, treatments, and vaccines.
Vaccine Effectiveness Studies in the Field
The original trials of vaccines against infection with severe acute respiratory disease coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), have clearly shown vac...
NIH Vaccine Research Center Leads the Way to ...
The Moderna vaccine for COVID-19 may seem like it developed quickly, but it was built on decades of research by NIH's Dale and Betty Bumpers Vaccine Research Center (VRC). The scientists of the VRC have learned from experience by studying the immune system and working on vaccines for other infectious diseases that pose major threats to human ...
Vaccine Effectiveness Studies
The goal of CDC's COVID-19 vaccine effectiveness program is to generate timely and robust evidence through observational studies under real-world conditions that inform COVID-19 vaccine policy. In collaboration with public health partners, CDC evaluates vaccine effectiveness through multiple observational studies employing a variety of ...
Persistence in risk and effect of COVID-19 vaccination on long-term
The persisting risk of long-term health consequences of SARS-CoV-2 infection and the protection against such risk conferred by COVID-19 vaccination remains unclear. Here we conducted a ...
Comparing the clinical efficacy of COVID-19 vaccines: a systematic
No vaccine was statistically significantly associated with a decreased risk for severe COVID-19 than other vaccines, although mRNA-1273 and Gam-COVID-Vac have the highest P-scores (0.899 and 0.816 ...
COVID vaccines and safety: what the research says
There is no question that the current vaccines are effective and safe. The risk of severe reaction to a COVID-19 jab, say researchers, is outweighed by the protection it offers against the deadly ...
Efficacy and safety of COVID-19 vaccines
2 Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE, Université de Paris, Paris, France. ... Over 300 registered RCTs are evaluating the efficacy of COVID-19 vaccines, and this review is updated regularly on the COVID-NMA platform (covid-nma.com). Implications for practice Due to the trial exclusions, these results ...
NIH-Sponsored Trial of Nasal COVID-19 Vaccine Opens
A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now enrolling healthy adults at three sites in the United States. The National Institutes of Health (NIH) is sponsoring the first-in-human trial of the investigational vaccine, which was designed and ...
Global research on coronavirus disease (COVID-19)
The R&D Blueprint has been activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus. ... The WHO COVID-19 Research Database was a resource created in response to the Public Health Emergency of International Concern (PHEIC). It contained citations with abstracts to scientific articles, reports, books, preprints ...
Get the facts about COVID-19 vaccines
These vaccines have U.S. Food and Drug Administration (FDA) emergency use authorization or approval. 2023-2024 Pfizer-BioNTech COVID-19 vaccine.. In December 2020, the Pfizer-BioNTech COVID-19 vaccine two-dose series was found to be both safe and effective in preventing COVID-19 infection in people age 18 and older.
Vaccines
Johns Hopkins International Vaccine Access Center. VIEW-hub is a publicly available interactive tool that displays up-to-date information on vaccine characteristics, and vaccine introduction and use globally. Vaccines include COVID-19 as well as many childhood vaccines in routine immunization programs. Understanding COVID-19.
Effectiveness of COVID‐19 vaccines: findings from real world studies
Community‐based studies in five countries show consistent strong benefits from early rollouts of COVID‐19 vaccines. By the beginning of June 2021, almost 11% of the world's population had received at least one dose of a coronavirus disease 2019 (COVID‐19) vaccine. 1 This represents an extraordinary scientific and logistic achievement — in 18 months, researchers, manufacturers and ...
NIH-sponsored trial of nasal COVID-19 vaccine opens
Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. NIAID. ... "The rapid development of safe and effective COVID-19 vaccines was a triumph of science, and their use greatly mitigated the toll of the pandemic," said NIAID Director Jeanne M. Marrazzo, M.D., M.P.H. "While first-generation COVID-19 ...
What to know about the next generation of COVID-19 vaccines
Challenges with the current vaccine. In December 2021, the U.S. Food and Drug Administration (FDA) authorized two new messenger RNA (mRNA) COVID-19 vaccines, from Pfizer-BioNTech and from Moderna ...
Covid-19
Explore KFF's policy research, polling, data and news on the COVID-19 pandemic, vaccines, and state-level policies.
Scientists closing in on why some people never get COVID. That could
Scientists describe high activity of a specific gene in volunteers who didn't get infected when exposed to COVID-19 on purpose. They hope better understanding early immune responses could help ...
CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall
It is safe to receive COVID-19 and flu vaccines at the same visit. Data continue to show the importance of vaccination to protect against severe outcomes of COVID-19 and flu, including hospitalization and death. In 2023, more than 916,300 people were hospitalized due to COVID-19 and more than 75,500 people died from COVID-19.
GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines
GSK has purchased the rights to COVID-19 and flu vaccines being developed in collaboration with German biotechnology company CureVac. GSK said it will pay CureVac as much as $1.56 billion to ...
Pregnancy and COVID-19: What are the risks?
Staying up to date on your COVID-19 vaccine helps prevent severe COVID-19 illness. It also may help a newborn avoid getting COVID-19 if you are vaccinated during pregnancy. People at higher risk of serious illness can talk to a healthcare professional about additional COVID-19 vaccines or other precautions.
IMAGES
VIDEO
COMMENTS
By the end of November 2021, scientists estimate that mRNA COVID-19 vaccines had prevented at least 1 million deaths, 10 million hospitalizations, and 36 million SARS-CoV-2 infections in the United States. Sometimes people who are fully vaccinated get a breakthrough infection, meaning that they test positive for SARS-CoV-2 or become ill with ...
The protective effects of vaccination and prior infection against severe Covid-19 are reviewed, with proposed directions for future research, including mucosal immunity and intermittent vaccine boo...
Safety and adverse effects of current COVID-19 vaccines. As shown in Table I, current vaccines have demonstrated considerable efficacy in diminishing mild, moderate and severe cases with a low risk of adverse events 21.For some of these vaccines [such as Convidicea (AD5-nCoV), Janssen (Ad26.COV2.S), Sinopharm (BBIBP-CorV), Covaxin (BBV152) and Sinovac (CoronaVac)], there is the information ...
Our analyses indicate that vaccine effectiveness generally decreases over time against SARS-CoV-2 infections, hospitalisations, and mortality. The baseline vaccine effectiveness levels for the omicron variant were notably lower than for other variants. Therefore, other preventive measures (eg, face-mask wearing and physical distancing) might be necessary to manage the pandemic in the long term.
Discussion. A two-dose regimen of BNT162b2 (30 μg per dose, given 21 days apart) was found to be safe and 95% effective against Covid-19. The vaccine met both primary efficacy end points, with ...
Abstract. The coronavirus disease 2019 (COVID-19) pandemic is a global crisis, with devastating health, business and social impacts. Vaccination is a safe, simple, and effective way of protecting a person against COVID-19. By the end of August 2021, only 24.6% of the world population has received two doses of a COVID-19 vaccine.
Now, given the urgent need for COVID-19 vaccines, unprecedented financial investments and scientific collaborations are changing how vaccines are developed. This means that some of the steps in the research and development process have been happening in parallel, while still maintaining strict clinical and safety standards.
COVID-19 vaccine development: an unprecedented timeframe. In the last decade, there was a marked evolution of vaccine platforms including the development of nucleic acid-based vaccine candidates and vectored vaccines, a number of approaches that have been used to accelerate COVID-19 vaccines elaboration.
Clinical trial results showed that the investigational vaccine known as mRNA-1273 is 94.1% effective in preventing symptomatic COVID-19. The findings suggest that the vaccine, which has now been FDA-approved for emergency use, is safe and effective. Results from a clinical trial showed that a COVID-19 vaccine developed by NIH and the biotech ...
The effectiveness of the mRNA vaccines in preventing COVID-19 disease progression in 2021 set new expectations about the role of prevention interventions for the disease. Efficacy observed in the trials was more than 90%.1,2 The efficacy of other vaccines evaluated in large randomised trials, such as the Oxford-AstraZeneca (70%) and Sputnik V (91%) vaccines, have been criticised for elements ...
Find COVID-19 datasets, data tools, and publications to use in research. EXPLORE COVID-19 DATA. Learn how NIH is supporting research in COVID-19 testing, treatments, and vaccines.
The original trials of vaccines against infection with severe acute respiratory disease coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), have clearly shown vac...
The Moderna vaccine for COVID-19 may seem like it developed quickly, but it was built on decades of research by NIH's Dale and Betty Bumpers Vaccine Research Center (VRC). The scientists of the VRC have learned from experience by studying the immune system and working on vaccines for other infectious diseases that pose major threats to human ...
The goal of CDC's COVID-19 vaccine effectiveness program is to generate timely and robust evidence through observational studies under real-world conditions that inform COVID-19 vaccine policy. In collaboration with public health partners, CDC evaluates vaccine effectiveness through multiple observational studies employing a variety of ...
The persisting risk of long-term health consequences of SARS-CoV-2 infection and the protection against such risk conferred by COVID-19 vaccination remains unclear. Here we conducted a ...
No vaccine was statistically significantly associated with a decreased risk for severe COVID-19 than other vaccines, although mRNA-1273 and Gam-COVID-Vac have the highest P-scores (0.899 and 0.816 ...
There is no question that the current vaccines are effective and safe. The risk of severe reaction to a COVID-19 jab, say researchers, is outweighed by the protection it offers against the deadly ...
2 Centre of Research in Epidemiology and Statistics (CRESS), INSERM, INRAE, Université de Paris, Paris, France. ... Over 300 registered RCTs are evaluating the efficacy of COVID-19 vaccines, and this review is updated regularly on the COVID-NMA platform (covid-nma.com). Implications for practice Due to the trial exclusions, these results ...
A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now enrolling healthy adults at three sites in the United States. The National Institutes of Health (NIH) is sponsoring the first-in-human trial of the investigational vaccine, which was designed and ...
The R&D Blueprint has been activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus. ... The WHO COVID-19 Research Database was a resource created in response to the Public Health Emergency of International Concern (PHEIC). It contained citations with abstracts to scientific articles, reports, books, preprints ...
These vaccines have U.S. Food and Drug Administration (FDA) emergency use authorization or approval. 2023-2024 Pfizer-BioNTech COVID-19 vaccine.. In December 2020, the Pfizer-BioNTech COVID-19 vaccine two-dose series was found to be both safe and effective in preventing COVID-19 infection in people age 18 and older.
Johns Hopkins International Vaccine Access Center. VIEW-hub is a publicly available interactive tool that displays up-to-date information on vaccine characteristics, and vaccine introduction and use globally. Vaccines include COVID-19 as well as many childhood vaccines in routine immunization programs. Understanding COVID-19.
Community‐based studies in five countries show consistent strong benefits from early rollouts of COVID‐19 vaccines. By the beginning of June 2021, almost 11% of the world's population had received at least one dose of a coronavirus disease 2019 (COVID‐19) vaccine. 1 This represents an extraordinary scientific and logistic achievement — in 18 months, researchers, manufacturers and ...
Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. NIAID. ... "The rapid development of safe and effective COVID-19 vaccines was a triumph of science, and their use greatly mitigated the toll of the pandemic," said NIAID Director Jeanne M. Marrazzo, M.D., M.P.H. "While first-generation COVID-19 ...
Challenges with the current vaccine. In December 2021, the U.S. Food and Drug Administration (FDA) authorized two new messenger RNA (mRNA) COVID-19 vaccines, from Pfizer-BioNTech and from Moderna ...
Explore KFF's policy research, polling, data and news on the COVID-19 pandemic, vaccines, and state-level policies.
Scientists describe high activity of a specific gene in volunteers who didn't get infected when exposed to COVID-19 on purpose. They hope better understanding early immune responses could help ...
It is safe to receive COVID-19 and flu vaccines at the same visit. Data continue to show the importance of vaccination to protect against severe outcomes of COVID-19 and flu, including hospitalization and death. In 2023, more than 916,300 people were hospitalized due to COVID-19 and more than 75,500 people died from COVID-19.
GSK has purchased the rights to COVID-19 and flu vaccines being developed in collaboration with German biotechnology company CureVac. GSK said it will pay CureVac as much as $1.56 billion to ...
Staying up to date on your COVID-19 vaccine helps prevent severe COVID-19 illness. It also may help a newborn avoid getting COVID-19 if you are vaccinated during pregnancy. People at higher risk of serious illness can talk to a healthcare professional about additional COVID-19 vaccines or other precautions.